Literature DB >> 16904298

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

Petros Skapinakis1, Tzeni Papatheodorou, Venetsanos Mavreas.   

Abstract

This study aimed to determine the effectiveness of antipsychotic augmentation of serotonergic antidepressants in the management of treatment-resistant obsessive compulsive disorder by carrying out a meta-analysis of all randomized controlled trials. Studies selected through a literature search conducted in March 2006. Ten trials comparing antipsychotic drugs versus placebo met inclusion criteria (haloperidol [n=1], risperidone [n=3], olanzapine [n=2], quetiapine [n=4]). A total of 157 patients were randomized to study drug and 148 were randomized to placebo. Response occurred more often among patients randomized to antipsychotic drugs. The weighted combined response rate ratio by random effects meta-analysis was 3.31 (95% CI 1.40-7.84). Significant between studies heterogeneity was partly explained by the definition of refractoriness, the type and dose of the drug used and the inclusion or exclusion of patients with tic disorders. The study supports the use of antipsychotic drugs as an augmentation strategy but more and larger trials are needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904298     DOI: 10.1016/j.euroneuro.2006.07.002

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  20 in total

Review 1.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

Review 2.  Obsessive compulsive disorder.

Authors:  G Mustafa Soomro
Journal:  BMJ Clin Evid       Date:  2012-01-18

3.  Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?

Authors:  Michael G Wheaton; David Rosenfield; Edna B Foa; H Blair Simpson
Journal:  J Consult Clin Psychol       Date:  2015-05-25

Review 4.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 5.  [Evidence-based pharmacotherapy and other somatic treatment approaches for obsessive-compulsive disorder: state of the art].

Authors:  A Kordon; B Zurowski; K Wahl; F Hohagen
Journal:  Nervenarzt       Date:  2011-03       Impact factor: 1.214

6.  Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood.

Authors:  Ulku Akyol Ardic; Eyup Sabri Ercan; Ayse Kutlu; Deniz Yuce; Melis Ipci; Sevim Berrin Inci
Journal:  Child Psychiatry Hum Dev       Date:  2017-10

Review 7.  Epidemiology and management of anxiety in patients with bipolar disorder.

Authors:  Marcia Kauer-Sant'Anna; Flavio Kapczinski; Eduard Vieta
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

Review 8.  The mouse who couldn't stop washing: pathologic grooming in animals and humans.

Authors:  Jamie D Feusner; Emily Hembacher; Katharine A Phillips
Journal:  CNS Spectr       Date:  2009-09       Impact factor: 3.790

9.  Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study.

Authors:  Haluk A Savas; Mehmet Yumru; Murat E Ozen
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 10.  Children with obsessive-compulsive disorder: are they just "little adults"?

Authors:  Simran K Kalra; Susan E Swedo
Journal:  J Clin Invest       Date:  2009-04-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.